Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304234 | 0.85 | SCN9A (0.46) | SCN9A | |
| SCHEMBL303716 | 0.84 | CYP17A1 (0.45) | CYP17A1CYP1A2SCN9ANPC1RAB9A | |
| SCHEMBL304064 | 0.82 | NR3C1 (0.47) | CYP17A1CYP1A2TSHRMAPT | |
| SCHEMBL25342945 | 0.81 | SCN9A (0.45) | CYP17A1CYP1A2SCN9AHDAC9 | |
| SCHEMBL30568648 | 0.74 | CYP17A1 (0.44) | CYP17A1CYP1A2SCN9AMAPK14TP53 | |
| SCHEMBL303854 | 0.73 | RAB9A (0.44) | CYP17A1CYP1A2NPC1RAB9AMAPT | |
| SCHEMBL25344855 | 0.72 | CYP17A1 (0.44) | CYP17A1CYP1A2MAPK14TP53MAPT | |
| SCHEMBL25342346 | 0.71 | CYP17A1 (0.60) | CYP17A1CYP1A2SCN9ARAB9A | |
| SCHEMBL4398029 | 0.70 | NPC1 (0.49) | NPC1RAB9ATSHRTP53MAPT | |
| SCHEMBL305521 | 0.69 | SCN9A (0.48) | CYP17A1CYP1A2SCN9AMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869003-B1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| EP-1869003-B1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-8093281-B2 | Indazoles as glucocorticoid receptor ligands | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093281-B2 | Indazoles as glucocorticoid receptor ligands | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093281-B2 | Indazoles as glucocorticoid receptor ligands | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1869003-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006108699-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, MC2R | CYP17A1 55/4885CYP1A2 260/4885SCN9A 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.